Recent investigations have converged on the overlap of GLP-1|GIP|GCGR activator therapies and dopamine signaling. While GLP agonists are increasingly employed for managing type 2 T2DM, their emerging impacts on reinforcement circuits, specifically governed by DA pathways, are attracting significa